Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor–Pretreated FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma: Case Report
Paolo d'Arienzo,Alan MacDonald,Virjen Patel,Yuk T Ma,Rille Pihlak,Naureen Starling
DOI: https://doi.org/10.2147/ott.s434449
IF: 4
2024-06-14
OncoTargets and Therapy
Abstract:Paolo D d'Arienzo, 1, &ast Alan R MacDonald, 1, &ast Virjen Patel, 2 Yuk T Ma, 3 Rille Pihlak, 4 Naureen Starling 1, 5 1 GI Cancers Unit, The Royal Marsden NHS Foundation Trust, London, UK; 2 Clinical Radiology Department, The Royal Marsden NHS Foundation Trust, London, UK; 3 Department of Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; 4 Department of Oncology, St Bartholomew's Hospital, London, UK; 5 Division of Clinical Studies, Institute of Cancer Research, London, UK &astThese authors contributed equally to this work Correspondence: Naureen Starling, GI Cancers Unit, The Royal Marsden Hospital, 203 Fulham Road, London, SW3 6JJ, United Kingdom, Email Multiple FGFR inhibitors have demonstrated significant activity in pretreated advanced FGFR2 fusion–positive intrahepatic cholangiocarcinoma. The irreversible pan-FGFR inhibitor futibatinib has the potential to overcome acquired resistance to ATP-competitive FGFR inhibitors in a subset of patients. We present a case of prolonged clinical benefit using FGFR inhibitors sequentially, initially an ATP-competitive inhibitor followed by futibatinib upon progression, for a total of 36 months of FGFR-targeting therapy. This case supports sequential FGFR-targeting therapies for FGFR2 fusion–positive cholangiocarcinoma, with futibatinib acting as rescue therapy after failure of ATP-competitive inhibitors. Keywords: cholangiocarcinoma, FGFR inhibitor, targeted therapy, futibatinib In 7%–15% of intrahepatic cholangiocarcinomas (iCCAs), rearrangements/fusions in the FGFR2 gene are detectable as an oncogenic driver. 1 Several oral FGFR inhibitors have been developed, including ATP-competitive inhibitors with activity against different FGFR receptors (pemigatinib, infigratinib, derazantinib, erdafitinib, Debio1347), irreversible pan-FGFR inhibitors (futibatinib, also known as TAS-120, and KIN-3248) and an irreversible FGFR2 specific inhibitor (RLY-4008). 2–4 Response rates of 20%–50% have been reported in phase I–II clinical trials with patients with advanced cholangiocarcinoma who had progressed on first-line platinum-based chemotherapy. 2,5–9 The FIGHT 202 trial led to FDA and EMA approval for the use of pemigatinib in pretreated advanced cholangiocarcinoma with FGFR2 fusion/rearrangements. Overall response rate (ORR) was 35.5%, median progression-free survival (mPFS) 6.9 months, and median duration of response (mDOR) 7.5 months. 5 In the same setting, treatment with derazantinib was associated with an ORR of 21.8%, mPFS of 7.8 months, and mDOR of 6.4 months. 7 FOENIX-CCA2, a phase II trial of futibatinib in chemotherapy-pretreated FGFR2 -rearranged iCCA with no previous FGFR-targeting therapy, has recently been reported with ORR 42%, mDOR 9.7 months, and mPFS 9 months. 9 Unfortunately, the emergence of acquired resistance to ATP-competitive FGFR inhibitors is common, and limits the duration of clinical benefit derived. On-target resistance mechanisms include the kinase domain gatekeeper mutations p. V565F, I, or L and molecular brakes, such as p. E566A, p. N550D, H, K, or T. Molecular brake mutations cause a rise in kinase activation, which interferes with the inhibitory effect of FGFR inhibitors, whereas gatekeeper mutations modify the binding pocket to prevent drug binding. 2,8,9 Off-target mechanisms include epithelial–mesenchymal transition, activation of alternative tyrosine kinase receptors, eg, EGFR, ERBB2/3, MET, and constitutional activation of alternative signalling pathways, ie, PI3K–Akt–mTOR, MAPK, JAK–STAT, and GSK3b. 2,10,11 Futibatinib is an irreversible FGFR inhibitor that forms a covalent adduct to a conserved cysteine residue in the ATP pocket of FGFR, leading to improved potency and specificity. 4 In vitro, futibatinib demonstrates activity against a wide range of mutations in the gatekeeper and molecular brake residues of the FGFR2 kinase domain. 10 In the phase I trial of futibatinib in solid tumours, 17.9% (5/28) of patients with FGFR2 -rearranged iCCA who had previously been treated with an FGFR inhibitor achieved a partial response, suggesting that this agent can overcome resistance mechanisms to earlier FGFR inhibitors. 8 A case series of four patients with FGFR2 -rearranged iCCA showed that treatment with futibatinib after progression on infigratinib or Debio1347 can lead to prolonged clinical benefit. 12 A further case report of treatment with futibatinib after progression on pemigatinib described a partial response and progression-free survival of 23 months. 13</ -Abstract Truncated-
oncology,biotechnology & applied microbiology